ML-12 MECHANISMS OF CELL DEATH INHIBITION THROUGH CHANGE IN SUBCELLULAR LOCALIZATION OF PIM-1 BY PIM1 GENE MUTATION RECURRENTLY FOUND IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

por Sasaki, Nobuyoshi, Ichimura, Koichi, Nagane, Motoo, Tomiyama, Arata
Publicado 2019

PATH-05. A CASE OF PILOCYTIC ASTROCYTOMA HARBORING THE FGFR1 GENE MUTATION WITH A PREDOMINANT OLIGODENDROGLIOMA-LIKE COMPONENT

por Sasaki, Nobuyoshi, Chiba, Tomohiro, Saito, Kuniaki, Kobayashi, Keiichi, Shiokawa, Yoshiaki, Shibahara, Junji, Nagane, Motoo
Publicado 2020

STMO-09 Recovery from speech deficit after injury to frontal aslant tract in glioma surgery

por Saito, Kuniaki, Kobayashi, Keiichi, Shimada, Daisuke, Iijima, Shohei, Sasaki, Nobuyoshi, Sasaki, Yuta, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2020

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status

por Tabei, Yusuke, Kobayashi, Keiichi, Saito, Kuniaki, Shimizu, Saki, Suzuki, Kaori, Sasaki, Nobuyoshi, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2020

STMO-9 Maximal safe glioma resection using high resolution exoscope

por Saito, Kuniaki, Sasaki, Nobuyoshi, Seiya, Yosuke, Onoda, Ryo, Kobayashi, Keiichi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2021

NQPC-5 Does high-dose methotrexate-based chemotherapy for relapsed primary CNS lymphoma increase a risk of leukoencephalopathy with prior whole brain radiotherapy?

por Kobayashi, Keiichi, Sasaki, Nobuyoshi, Saito, Kuniaki, Yamagishi, Yuki, Hanayama, Naomi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2021

NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA

por Yamagishi, Yuki, Hanayama, Naomi, Sasaki, Nobuyoshi, Saito, Kuniaki, Kobayashi, Keiichi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2022

ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid

por Yamagishi, Yuki, Sasaki, Nobuyoshi, Matsushita, Yuko, Shimizu, Saki, Saito, Kuniaki, Kobayashi, Keiichi, Shiokawa, Yoshiaki, Nagane, Motoo, Ichimura, Koichi
Publicado 2020

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma

por Kobayashi, Keiichi, Sasaki, Nobuyoshi, Saito, Kuniaki, Yamagishi, Yuki, Matsumoto, Yoshie, Sasaki, Yuta, Shimizu, Saki, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2020

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma

por Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Sasaki, Yuta, Okamura, Yuma, Yamagishi, Yuki, Shimizu, Saki, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2020

ML-02 MULTIAGENT IMMUNOCHEMOTHERAPY, R-MPV-A, FOR PATIENTS WITH SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

por Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimada, Daisuke, Matsumoto, Yoshie, Iijima, Shohei, Sasaki, Nobuyoshi, Yamagishi, Yuki, Takayama, Nobuyuki, Shiokawa, Yoshiaki
Publicado 2019

ML-12 Clinical impact and management of skin-related disorders during treatment of relapsed PCNSL by tirabrutinib

por Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Onoda, Ryo, Seiya, Yosuke, Suzuki, Saki, Yamagishi, Yuki, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Nagane, Motoo
Publicado 2021

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma

por Nagane, Motoo, Sasaki, Nobuyoshi, Kobayashi, Keiichi, Saito, Kuniaki, Shimada, Daisuke, Matsumoto, Yoshie, Iijima, Shohei, Yamagishi, Yuki, Shimizu, Saki, Sasaki, Yuta, Shiokawa, Yoshiaki
Publicado 2020

CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma

por Tateishi, Kensuke, Miyake, Yohei, Kawazu, Masahito, Nakamura, Taishi, Sasaki, Nobuyoshi, Sasame, Jo, Yoshii, Yukie, Wakimoto, Hiroaki, Nagane, Motoo, Ichimura, Koichi, Yamamoto, Tetsuya
Publicado 2020

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma

por Nagane, Motoo, Sasaki, Nobuyoshi, Saito, Kuniaki, Kobayashi, Keiichi, Onoda, Ryo, Seiya, Yosuke, Yamagishi, Yuki, Nakatomi, Hirofumi, Ohnishi, Hiroaki, Takayama, Nobuyuki, Shiokawa, Yoshiaki
Publicado 2021

ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma

por Yuki, Yamagishi, Sasaki, Nobuyoshi, Matsushita, Yuko, Shimizu, Saki, Matsumoto, Yoshie, Saito, Kuniaki, Kobayashi, Keiichi, Nakatomi, Hirofumi, Shiokawa, Yoshiaki, Ichimura, Koichi, Nagane, Motoo
Publicado 2021

Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death

por YAMAMOTO, Yutaro, SASAKI, Nobuyoshi, KUMAGAI, Kosuke, TAKEUCHI, Satoru, TOYOOKA, Terushige, OTANI, Naoki, WADA, Kojiro, NARITA, Yoshitaka, ICHIMURA, Koichi, NAMBA, Hiroki, MORI, Kentaro, TOMIYAMA, Arata
Publicado 2018

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma

por Yamagishi, Yuki, Sasaki, Nobuyoshi, Nakano, Yoshiko, Matushita, Yuko, Omura, Takaki, Shimizu, Saki, Saito, Kuniaki, Kobayashi, Keiichi, Narita, Yoshitaka, Kondo, Akihide, Shiokawa, Yoshiaki, Nagane, Motoo, Ichimura, Koichi
Publicado 2021

TB-02 NF-KB CANONICAL PATHWAY ACTIVATION DRIVES GLYCOLYSIS AND TUMOR PROGRESSION IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

por Tateishi, Kensuke, Sasaki, Nobuyoshi, Kawazu, Masahito, Miyake, Yohei, Nakamura, Taishi, Yoshii, Yukie, Matsushita, Yuko, Miyake, Shigeta, Sasame, Jo, Yamanaka, Shoji, Yamamoto, Tetsuya, Wakimoto, Hiroaki, Nagane, Motoo, Ichimura, Koichi
Publicado 2019

Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance

por Yamamuro, Shun, Takahashi, Masamichi, Satomi, Kaishi, Sasaki, Nobuyoshi, Kobayashi, Tatsuya, Uchida, Eita, Kawauchi, Daisuke, Nakano, Tomoyuki, Fujii, Takashi, Narita, Yoshitaka, Kondo, Akihide, Wada, Kojiro, Yoshino, Atsuo, Ichimura, Koichi, Tomiyama, Arata
Publicado 2021